TNFRSF8 and Hodgkins lymphoma: Besides, CD30 was also a promising target for classical Hodgkin lymphoma (HL), two phase I/II studies of CD30 CAR-T cells showed that the best ORR of 37 evaluable R/R HL patients was 62% with 19 patients having a CR and 4 patients having a PR (41).